Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 5/2016

01-05-2016 | Original Article

Lobar distribution in non-cystic fibrosis bronchiectasis predicts bacteriologic pathogen treatment

Authors: S. Izhakian, W. G. Wasser, L. Fuks, B. Vainshelboim, B. D. Fox, O. Fruchter, M. R. Kramer

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 5/2016

Login to get access

Abstract

Non-cystic fibrosis bronchiectasis (NCFBr) is a major cause of morbidity due to frequent infectious exacerbations. We analyzed the influence of patient age and bronchiectasis location on the bacterial profile of patients with NCFBr. This retrospective cohort study included 339 subjects diagnosed with an infectious exacerbation of NCFBr during the 9-year period between January 2006 and December 2014. Bronchoalveolar lavage (BAL) cultures and high-resolution computed tomography scans (HRCT) were utilized to characterize the location of the bronchiectasis and bacteriologic pathogenic profile. In univariate logistic regression, the frequency of Haemophilus influenzae was higher in patients aged ≤64 years (OR = 0.969, p < 0.0001, 95 % CI 0.954–0.983), whereas the frequency of Pseudomonas aeruginosa (OR = 1.027, p = 0.008, 95 % CI 1.007–1.048) and Enterobacteriaceae (OR = 1.039, p = 0.01, 95 % CI 1.009–1.069) were significantly higher in patients aged >64 years. The lobar distribution of bronchiectasis in the subjects was 25.9 % in the right middle lobe (RML), 20.7 % in the right lower lobe (RLL), 20.4 % in the left lower lobe (LLL), 13.8 % in the lingula, 13 % in the right upper lobe (RUL), and 6.2 % in the left upper lobe (LUL). In the lower lobes, H. influenzae was the dominant species isolated, whereas in the RUL it was P. aeruginosa and in the LUL it was non- tuberculous mycobacterium (NTM). H. influenzae was more prevalent in younger patients, whereas P. aeruginosa, Enterobacteriaceae and NTM predominated in older patients. Different pathogens were associated with different lobar distributions. The RML, RLL and LLL showed a greater tendency to develop bronchiectasis than other lobes.
Literature
2.
go back to reference Angrill J, Agusti C, de Celis R, Rano A, Gonzalez J, Sole T, Xaubet A, Rodriguez-Roisin R, Torres A (2002) Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 57(1):15–19CrossRefPubMedPubMedCentral Angrill J, Agusti C, de Celis R, Rano A, Gonzalez J, Sole T, Xaubet A, Rodriguez-Roisin R, Torres A (2002) Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 57(1):15–19CrossRefPubMedPubMedCentral
3.
go back to reference Palwatwichai A, Chaoprasong C, Vattanathum A, Wongsa A, Jatakanon A (2002) Clinical, laboratory findings and microbiologic characterization of bronchiectasis in Thai patients. Respirology 7(1):63–66CrossRefPubMed Palwatwichai A, Chaoprasong C, Vattanathum A, Wongsa A, Jatakanon A (2002) Clinical, laboratory findings and microbiologic characterization of bronchiectasis in Thai patients. Respirology 7(1):63–66CrossRefPubMed
4.
go back to reference Wilson CB, Jones PW, O'Leary CJ, Hansell DM, Cole PJ, Wilson R (1997) Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 10(8):1754–1760CrossRefPubMed Wilson CB, Jones PW, O'Leary CJ, Hansell DM, Cole PJ, Wilson R (1997) Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 10(8):1754–1760CrossRefPubMed
6.
go back to reference McDonnell MJ, Jary HR, Perry A, MacFarlane JG, Hester KL, Small T, Molyneux C, Perry JD, Walton KE, De Soyza A (2015) Non cystic fibrosis bronchiectasis: a longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance. Respir Med 109(6):716–726. doi:10.1016/j.rmed.2014.07.021 CrossRefPubMed McDonnell MJ, Jary HR, Perry A, MacFarlane JG, Hester KL, Small T, Molyneux C, Perry JD, Walton KE, De Soyza A (2015) Non cystic fibrosis bronchiectasis: a longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance. Respir Med 109(6):716–726. doi:10.​1016/​j.​rmed.​2014.​07.​021 CrossRefPubMed
7.
go back to reference McGuinness G, Naidich DP (2002) CT of airways disease and bronchiectasis. Radiol Clin North Am 40(1):1–19CrossRefPubMed McGuinness G, Naidich DP (2002) CT of airways disease and bronchiectasis. Radiol Clin North Am 40(1):1–19CrossRefPubMed
8.
go back to reference National Committee for Clinical Laboratory Standards (1998) Performance standards for antimicrobial susceptibility testing; NCCLS document M100-S8, 18(1). The Committee; 8th information supplement, Villanova National Committee for Clinical Laboratory Standards (1998) Performance standards for antimicrobial susceptibility testing; NCCLS document M100-S8, 18(1). The Committee; 8th information supplement, Villanova
9.
10.
go back to reference Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker JE, Coulden RA, Flower CD, Bilton D, Keogan MT (2000) An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 162(4 Pt 1):1277–1284CrossRefPubMed Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker JE, Coulden RA, Flower CD, Bilton D, Keogan MT (2000) An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 162(4 Pt 1):1277–1284CrossRefPubMed
11.
12.
go back to reference Wickremasinghe M, Ozerovitch L, Davies G, Wodehouse T, Chadwick M, Abdallah S, Shah P, Wilson R (2005) Non-tuberculous mycobacteria in patients with bronchiectasis. Thorax 60(12):1045–1051CrossRefPubMedPubMedCentral Wickremasinghe M, Ozerovitch L, Davies G, Wodehouse T, Chadwick M, Abdallah S, Shah P, Wilson R (2005) Non-tuberculous mycobacteria in patients with bronchiectasis. Thorax 60(12):1045–1051CrossRefPubMedPubMedCentral
Metadata
Title
Lobar distribution in non-cystic fibrosis bronchiectasis predicts bacteriologic pathogen treatment
Authors
S. Izhakian
W. G. Wasser
L. Fuks
B. Vainshelboim
B. D. Fox
O. Fruchter
M. R. Kramer
Publication date
01-05-2016
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 5/2016
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-016-2599-7

Other articles of this Issue 5/2016

European Journal of Clinical Microbiology & Infectious Diseases 5/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.